ARTICLE | Company News
Britannia, Ipsen sales and marketing update
November 7, 2011 8:00 AM UTC
Britannia acquired North American commercialization rights from Ipsen for Apokyn apomorphine to treat "off" episodes associated with Parkinson's disease (PD). Ipsen said that Britannia will pay $10 m...